SCHEMBL30795291

SCHEMBL30795291

Cc1ccc2c(c1)C(c1ccccc1)N(C(=O)CCC(=O)Nc1ccccc1Cl)CC2

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 2/20 0.50
▸ HHAT Q5VTY9 4/20 0.49
▸ ALDH1A1 P00352 3/20 0.46
▸ LMNA P02545 2/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ MITF O75030 1/20 0.46
▸ XBP1 P17861 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ L3MBTL1 Q9Y468 3/20 0.44
▸ KIF11 P52732 1/20 0.44
▸ CYP2D6 P10635 1/20 0.43
▸ HPGD P15428 1/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3242955 1.00 TP53 (0.50) TP53HHATALDH1A1LMNANPC1
SCHEMBL3229592 0.88 HHAT (0.53) HHATL3MBTL1CYP2D6KMT2AMEN1
SCHEMBL30795471 0.88 HHAT (0.53) HHATL3MBTL1CYP2D6KMT2AMEN1
SCHEMBL3242926 0.86 TP53 (0.45) TP53ALDH1A1LMNANPC1MITF
SCHEMBL30794386 0.86 TP53 (0.45) TP53ALDH1A1LMNANPC1MITF
SCHEMBL3236426 0.83 LMNA (0.53) HHATALDH1A1LMNANPC1MITF
SCHEMBL3242167 0.82 POLB (0.43) TP53HHATALDH1A1HTTKMT2A
SCHEMBL30795671 0.82 POLB (0.43) TP53HHATALDH1A1HTTKMT2A
SCHEMBL3242927 0.82 HHAT (0.49) HHATALDH1A1LMNANPC1MITF
SCHEMBL3231197 0.82 PKM (0.49) TP53HHATALDH1A1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 — — EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 — — EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 — — WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 — — WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 — — WO disclosed
Send feedback